Last reviewed · How we verify
ATG + CSA
ATG (antithymocyte globulin) and CSA (cyclosporine A) together provide immunosuppression by depleting T cells and inhibiting T cell activation, respectively.
ATG (antithymocyte globulin) and CSA (cyclosporine A) together provide immunosuppression by depleting T cells and inhibiting T cell activation, respectively. Used for Graft-versus-host disease (GVHD) prevention or treatment, Hematopoietic stem cell transplantation conditioning.
At a glance
| Generic name | ATG + CSA |
|---|---|
| Sponsor | Swiss Cancer Institute |
| Drug class | Immunosuppressive combination therapy |
| Target | T lymphocytes (ATG); Calcineurin (CSA) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
ATG is a polyclonal antibody that binds to and depletes T lymphocytes, reducing the cellular immune response. Cyclosporine A inhibits calcineurin, blocking T cell receptor signaling and IL-2 production. Combined, they provide potent immunosuppression used primarily in transplantation and severe autoimmune conditions.
Approved indications
- Graft-versus-host disease (GVHD) prevention or treatment
- Hematopoietic stem cell transplantation conditioning
Common side effects
- Infection (bacterial, viral, fungal)
- Cytopenias (thrombocytopenia, leukopenia)
- Nephrotoxicity
- Hypertension
- Neurotoxicity
Key clinical trials
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (PHASE2)
- Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (PHASE2)
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (NA)
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (PHASE3)
- A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia (PHASE2)
- Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |